Global Chromoblastomycosis Treatment Market Size, Share, Forecast Report, 2020-2027

Chromoblastomycosis is a fungal infection caused by species such as Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola and others. This disease mostly affects the skin and the subcutaneous tissues. Globally, there is about a million type of fungal species, yet nearly 300 are capable of causing infections or disease in humans. Most of these cases are seen in people with compromised immune systems and can occur almost in any part of the body.

A type of fungal infection known as systemic mycosis is affecting the internal organs of the body. During this, fungal infection can spread and affect other organs of the body. The rising cases of immunological diseases is a reason for increased probability of systemic mycosis. Thus, the developing novel treatment for chromoblastomycosis with fewer side effects is the primary objective of manufacturing companies.

The newly launched azoles such as voriconazole and itraconazole, are the gold standard drugs for antifungal therapy. Chromoblastomycosis infections need to be treated with antifungal medication such as itraconazole, terbinafine, posaconazole, amphotericin B. Often, the treatment for chromoblastomycosis requires surgery to scrape off the infected tissue. The growth of the Chromoblastomycosis treatment market is primarily driven by increasing incidents of fungal infections, rising prevalence of immunological diseases, availability of wide range of products, and increasing awareness about the fungal infections. However, the existence of misbranded drugs and their side effects may slow the growth of the market. The treatment of fungal infections is available in multiple dosage forms such as oral and intravenous medicines. Furthermore, the medications are also available in the form of sprays, creams, solutions, and shampoos.

The global market for chromoblastomycosis treatment is expected to grow at a CAGR of approximately 6.3% during the forecast period, 2017-2023.
Segmentation

The global chromoblastomycosis treatment market is segmented on the basis of species, types, diagnosis, treatment, and end-users.

On the basis of the species, the global chromoblastomycosis treatment market is segmented into Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola, and others.

On the basis of the disease type, the global chromoblastomycosis treatment market is segmented into nodular type, tumoral type, verrucous type, plaque type, and others.

On the basis of the diagnosis, the global chromoblastomycosis treatment market is segmented into blood test, immunodiagnosis, histopathology and mycological examination, tissue biopsy, and others. The immunodiagnosis is classified into enzyme-linked immune sorbent assay (ELISA), and immunodiffusion, and others.

On the basis of the treatment, the global chromoblastomycosis treatment market is segmented into surgery, antifungal drugs, amphotericin B therapy, thermotherapy, laser therapy, photodynamic therapy, adjuvant therapy, and others. The surgery is classified into cryosurgery, curettage, electrodesiccation, surgical excisions, and others. Furthermore, the antifungal drugs are categorized into oral itraconazole, oral terbinafine, posaconazole, isavuconazole, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
Key Players

Some of key the players in the global chromoblastomycosis treatment market are Astellas Pharma (Japan), Biocon Limited (India), Abbott Laboratories (U.S.), Merck Sharp and Dohme (U.S.), Gilead Sciences (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.), Bayer AG (Germany), Lonza Group (Switzerland), Sanofi (France), F. Hoffman La Roche (Switerzland), Cadila Pharmaceuticals Limited (India), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switerzland), and others